Dentsply Sirona: 3 Key Takeaways for Long-Term Investors

Source Motley_fool

Key Points

  • Management reduced full-year 2026 sales guidance to approximately $3.5 billion.

  • Wellspect Healthcare revenue grew 10% year over year to $92 million.

  • Clinical education investments in North America increased sixfold year over year.

  • Motley Fool Issues Rare "Total Conviction" Buy Alert ›

On its third-quarter 2026 earnings call, held on Nov. 5, 2026, Dentsply Sirona (NASDAQ:XRAY) announced lower full-year net sales and earnings guidance. Revenue fell 7.6% as reported, driven by weakness across dental equipment lines. Long-term investors must weigh these operational headwinds against ongoing investments in commercial sales teams and product innovation.

Three things management said stand out.

1. Full-Year Revenue and Earnings Guidance Crept Lower

Management lowered its net sales expectations to approximately $3.5 billion and reduced adjusted earnings per share, a key profitability metric, to between $1.20 to $1.30. Higher distribution costs and weaker equipment demand created headwind pressures that extra cost cuts didn't fully offset.

We now expect full-year net sales of approximately $3.5 billion versus the range of $3.5 billion-$3.6 billion previously, and adjusted EPS of $1.20-$1.30 from $1.40-$1.50, excluding the $0.17 one-time gain from tariff refunds.
-- Dan Scavilla, President and Chief Executive Officer

2. Heavy Clinical Education Spending Aims to Fuel Long-Term Adoption

Management multiplied its spending on clinical training programs in North America to build practitioner loyalty and drive usage across its endodontic, or root canal treatment, product line. This commercial strategy prioritizes product adoption over short-term operating margin expansion.

Our second half 2026 clinical education investment in North America is six times greater than last year's level, including more than 160 endo courses and expanded hands-on programs.
-- Dan Scavilla, President and Chief Executive Officer

3. Commercial Execution Drives Growth in Wellspect Healthcare

The Wellspect Healthcare business, which produces continent urinary catheter products, delivered 10% revenue growth during the quarter to reach $92 million. Focused commercial spending expanded the division's reach in the $7 billion market.

Investments in new products and U.S. commercial capabilities are supporting broader market reach and continued growth.
-- Dan Scavilla, President and Chief Executive Officer

Looking Ahead

Green shoots in U.S. dental implants and restorative lines signal initial operational progress, and leadership is pushing to convert these early gains into sustainable organic momentum. The business continues building out dedicated teams for dental support organizations, which are corporate dental practice chains, while sharpening research and development discipline. Management is tracking distributor inventory levels, sales force vacancy rates, and pricing discipline to evaluate progress.

The task is now to extend that progress across the portfolio and deliver more consistent results.
-- Dan Scavilla, President and Chief Executive Officer

Stabilizing core equipment sales while maintaining cost control remains central to deleveraging, which means paying down debt to improve financial flexibility. Capital allocation priorities lean heavily toward debt reduction alongside disciplined reinvestment in commercial execution.

My priorities are to translate these capabilities into more consistent execution, disciplined investment, and stronger cash generation.
-- John Fortson, Executive Vice President and Chief Financial Officer

Should you buy stock in Dentsply Sirona right now?

Before you buy stock in Dentsply Sirona, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Dentsply Sirona wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $335,171!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,000,640!*

Now, it’s worth noting Stock Advisor’s total average return is 823% — a market-crushing outperformance compared to 208% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of November 16, 2026.

The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Anthropic Launches New Fable, Mythos Models Ahead of IPO: Up to 30% Speed Boost Poised to Support Offering ValuationTradingKey - Anthropic released Claude Fable 5.2 and Claude Mythos 5.2 on November 9, upgrading their coding, reasoning, and vision capabilities while lowering usage prices. The company stated that ou
Author  TradingKey
Nov 10, Tue
TradingKey - Anthropic released Claude Fable 5.2 and Claude Mythos 5.2 on November 9, upgrading their coding, reasoning, and vision capabilities while lowering usage prices. The company stated that ou
placeholder
Nvidia Enters Bear Market As Google Strikes Amid Jensen Huang's China Spy WoesNvidia, the engine of the AI boom, is in a bear market. Shares sank to about $177 on Monday, 26% below their October record, as a China spy scandal reached its CEO.A bear market means a fall of 20% or
Author  Beincrypto
Nov 10, Tue
Nvidia, the engine of the AI boom, is in a bear market. Shares sank to about $177 on Monday, 26% below their October record, as a China spy scandal reached its CEO.A bear market means a fall of 20% or
placeholder
Nvidia CEO Probe Hit Binance Stock Perps While Wall Street Was ClosedThe probe into Nvidia CEO Jensen Huang broke over the weekend, while Wall Street was closed. Crypto traders still priced it in early. Binance’s Nvidia perpetual futures fell more than 4% below the las
Author  Beincrypto
Nov 10, Tue
The probe into Nvidia CEO Jensen Huang broke over the weekend, while Wall Street was closed. Crypto traders still priced it in early. Binance’s Nvidia perpetual futures fell more than 4% below the las
placeholder
Tesla and SpaceX Stocks Fall as Investors Worry About Elon Musk’s Political RiskWhile the US stock market surged on Wednesday, SpaceX and Tesla stocks were sliding. Democrats won both chambers of Congress and the Texas governor’s race, defeats that land squarely on Elon Musk’s co
Author  Beincrypto
Nov 05, Thu
While the US stock market surged on Wednesday, SpaceX and Tesla stocks were sliding. Democrats won both chambers of Congress and the Texas governor’s race, defeats that land squarely on Elon Musk’s co
placeholder
Brent Crude Plunges 10% Near $90 Level: What Caused the Rapid Drop in Oil Prices?TradingKey - On Wednesday, November 4, Eastern Time, crude oil prices fell sharply, with Brent crude (UKOIL) approaching $93, down over 10% intraday; WTI crude (USOIL) fell below the $87 mark, down mo
Author  TradingKey
Nov 05, Thu
TradingKey - On Wednesday, November 4, Eastern Time, crude oil prices fell sharply, with Brent crude (UKOIL) approaching $93, down over 10% intraday; WTI crude (USOIL) fell below the $87 mark, down mo
goTop
quote